IMO, I don’t think posting revenue predictions is too far out of line for CYDY. Leronlimab successfully completed a phase 3 with flying colors and we have no reason to doubt its approval. Is there a chance the BLA will be returned for corrections, etc.? Sure, but there is not a single item that is negative about leronlimab that would lead to its non-approval.

Now, predicting revenues for NASH or GvHD would be out of line as neither phase 2 trial has even started. Predictions for cancer may be too early as well.